TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

July 22, 2026

The General Manager
Department of Corporate Services,
BSE Ltd., Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526139 Respected Sir / Madam,

Subject: **Intimation of the Board Meeting**.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of Transgene Biotek Limited is scheduled to be held on **Friday, August 07, 2026**, inter alia, to consider and approve the following matters:

1. To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30, 2026.
2. To consider and approve the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.
3. To consider and approve seeking an extension of time for holding the Annual General Meeting (AGM) of the Company for the Financial Year 2025-26.
4. To consider and approve the appointment of the internal auditor of the Company for financial year 2026-27.
5. To transact such other business as may be required.

Further, we wish to inform you that as per the Code of Conduct adopted by the Company, to regulate, monitor and report trading by insiders, pursuant to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Trading Window for dealing in the securities of the Company was already closed from 1st July, 2026 till 48 hours after the financial results of the Company for the quarter ended on 30th June, 2026 and becomes a generally available information.

This is for your information and records. Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Plot 69 & 70, IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-8458-279744 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195AP1990PLC011065